Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

853
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
853

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromosomal instability drives immunosuppression and metastatic dissemination.

Cell research·2023
Same author

Molecular determinants of immunogenic cell death elicited by radiation therapy.

Immunological reviews·2023
Same author

Type I interferon and cancer.

Immunological reviews·2023
Same author

Interferon signaling restrains renal cell carcinoma heterogeneity.

Trends in cancer·2023
Same author

BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.

Cancer discovery·2023
Same author

Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.

Trends in cancer·2023

Related Experiment Video

Updated: May 2, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids.

Maud Charpentier1, Norma Bloy1, Silvia C Formenti2

  • 1Department of Radiation Oncology, Weill Cornell Medical College.

Journal of Visualized Experiments : Jove
|April 22, 2024
PubMed
Summary

This study presents a new method to measure cancer cell radiosensitivity using patient-derived tumor organoids (PDTOs). This technique adapts clonogenic assays for PDTOs, enabling accurate assessment of radiation therapy effectiveness.

More Related Videos

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.2K
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

819

Related Experiment Videos

Last Updated: May 2, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.2K
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

819

Area of Science:

  • Oncology
  • Radiation Biology
  • Cancer Research

Background:

  • Radiation therapy (RT) is a cornerstone of cancer treatment, but cancer cell radiosensitivity varies.
  • Assessing radiosensitivity is crucial for effective cancer management.
  • Traditional clonogenic assays are unsuitable for complex models like patient-derived tumor organoids (PDTOs).

Purpose of the Study:

  • To adapt clonogenic assays for evaluating radiosensitivity in patient-derived tumor organoids (PDTOs).
  • To develop a method that accurately reflects cancer cell response to ionizing radiation within a tumor microenvironment.

Main Methods:

  • Established PDTOs were exposed to ionizing radiation.
  • Irradiated PDTOs were dissociated into single cells for replating.
  • Live imaging and time-lapse microscopy were used to quantify PDTO-forming efficiency and growth rate.

Main Results:

  • PDTO-forming efficiency of stem-like cells was dose-dependently reduced by irradiation.
  • PDTO-forming efficiency and growth rate served as quantifiable measures of radiosensitivity.
  • The adapted assay accurately assesses radiosensitivity in PDTO models.

Conclusions:

  • The developed method provides a reliable way to measure PDTO radiosensitivity.
  • This technique overcomes limitations of traditional assays for complex tumor models.
  • Accurate radiosensitivity assessment in PDTOs can improve personalized cancer therapy strategies.